Bicycle Therapeutics is a clinical-stage pharmaceutical company that develops Bicycle molecules—fully synthetic short peptides designed to bind specific disease targets with high affinity and selectivity. The company leverages a proprietary phage display screening platform to efficiently identify and develop these molecules, which combine the pharmacology of biologics with the manufacturing advantages and rapid kidney excretion of small molecules. Bicycle's pipeline includes internal oncology programs based on drug conjugates and radioconjugates, along with strategic collaborations with major pharmaceutical partners like Ionis and Bayer to extend the platform to new therapeutic areas, and the company plans to commercialize its candidates either independently or through partnerships.